|
1
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al CONCORD Working Group: Global surveillance of cancer survival
1995–2009: Analysis of individual data for 25,676,887 patients from
279 population-based registries in 67 countries (CONCORD-2).
Lancet. 385:977–1010. 2015. View Article : Google Scholar
|
|
2
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashimoto Y, Akiyama Y and Yuasa Y:
Multiple-to-multiple relationships between microRNAs and target
genes in gastric cancer. PLoS One. 8:e625892013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo X, Xia J and Yan J: Promoter
methylated microRNAs: Potential therapeutic targets in gastric
cancer. Mol Med Rep. 11:759–765. 2015. View Article : Google Scholar
|
|
5
|
Olive V, Bennett MJ, Walker JC, Ma C,
Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ and He L: miR-19
is a key oncogenic component of mir-17–92. Genes Dev. 23:2839–2849.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olive V, Jiang I and He L: mir-17–92, a
cluster of miRNAs in the midst of the cancer network. Int J Biochem
Cell Biol. 42:1348–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Woods K, Thomson JM and Hammond SM: Direct
regulation of an oncogenic micro-RNA cluster by E2F transcription
factors. J Biol Chem. 282:2130–2134. 2007. View Article : Google Scholar
|
|
8
|
Tili E, Michaille JJ, Liu CG, Alder H,
Taccioli C, Volinia S, Calin GA and Croce CM: GAM/ZFp/ZNF512B is
central to a gene sensor circuitry involving cell-cycle regulators,
TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic
potentials. Nucleic Acids Res. 38:7673–7688. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dews M, Homayouni A, Yu D, Murphy D,
Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et
al: Augmentation of tumor angiogenesis by a Myc-activated microRNA
cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dakhlallah D, Batte K, Wang Y,
Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright
VP, Nana-Sinkam SP, et al: Epigenetic regulation of miR-17~92
contributes to the pathogenesis of pulmonary fibrosis. Am J Respir
Crit Care Med. 187:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y
and Fan D: Methylation of miR-129-5p CpG island modulates
multi-drug resistance in gastric cancer by targeting ABC
transporters. Oncotarget. 5:11552–11563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang F, Li T, Zhang B, Li H, Wu Q, Yang L,
Nie Y, Wu K, Shi Y and Fan D: MicroRNA-19a/b regulates multidrug
resistance in human gastric cancer cells by targeting PTEN. Biochem
Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z,
Meng D and Wang Y: Differential expression of microRNA species in
human gastric cancer versus non-tumorous tissues. J Gastroenterol
Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y
and Fan D: MiR-19b/20a/92a regulates the self-renewal and
proliferation of gastric cancer stem cells. J Cell Sci.
126:4220–4229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P,
Nie Y, Wu K, Shi Y and Fan D: MiR-19a/b modulate the metastasis of
gastric cancer cells by targeting the tumour suppressor MXD1. Cell
Death Dis. 5:e11442014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Gao H, Ren L, Gu J and Zhang Y and
Zhang Y: Demethylation of the miR-146a promoter by
5-Aza-2′-deoxycytidine correlates with delayed progression of
castration-resistant prostate cancer. BMC Cancer. 14:3082014.
View Article : Google Scholar
|
|
17
|
Liu J, Zhang X, Liu A, Zhang D, Su Y, Liu
Y, You D, Yuan L, Kong X, Wang X, et al: Altered methylation of
glucosylceramide synthase promoter regulates its expression and
associates with acquired multidrug resistance in invasive ductal
breast cancer. Oncotarget. 7:36755–36766. 2016.PubMed/NCBI
|
|
18
|
Chen KG and Sikic BI: Molecular pathways:
Regulation and therapeutic implications of multidrug resistance.
Clin Cancer Res. 18:1863–1869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang JY, Lu R, Mikovits JA, Cheng ZH, Zhu
HY and Chen YX: Regulation of hMSH2 and hMLH1 expression in the
human colon cancer cell line SW1116 by DNA methyltransferase 1.
Cancer Lett. 233:124–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu MX, Siu MK, Liu SS, Yam JW, Ngan HY
and Chan DW: Epigenetic silencing of microRNA-199b-5p is associated
with acquired chemoresistance via activation of JAG1-Notch1
signaling in ovarian cancer. Oncotarget. 5:944–958. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neupane M, Clark AP, Landini S, Birkbak
NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE,
Beroukhim R, et al: MECP2 is a frequently amplified oncogene with a
novel epigenetic mechanism that mimics the role of activated RAS in
malignancy. Cancer Discov. 6:45–58. 2016. View Article : Google Scholar :
|
|
22
|
Du Q, Luu PL, Stirzaker C and Clark SJ:
Methyl-CpG-binding domain proteins: Readers of the epigenome.
Epigenomics. 7:1051–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sansom OJ, Maddison K and Clarke AR:
Mechanisms of disease: Methyl-binding domain proteins as potential
therapeutic targets in cancer. Nat Clin Pract Oncol. 4:305–315.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El-Osta A, Kantharidis P, Zalcberg JR and
Wolffe AP: Precipitous release of methyl-CpG binding protein 2 and
histone deacetylase 1 from the methylated human multidrug
resistance gene (MDR1) on activation. Mol Cell Biol. 22:1844–1857.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wada R, Akiyama Y, Hashimoto Y, Fukamachi
H and Yuasa Y: miR-212 is downregulated and suppresses
methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J
Cancer. 127:1106–1114. 2010. View Article : Google Scholar
|
|
26
|
Tong D, Zhao L, He K, Sun H, Cai D, Ni L,
Sun R, Chang S, Song T and Huang C: MECP2 promotes the growth of
gastric cancer cells by suppressing miR-338-mediated
antiproliferative effect. Oncotarget. 7:34845–34859. 2016.
View Article : Google Scholar : PubMed/NCBI
|
